Analysis of Legal Verbiage in State Legislation for Insurer Coverage of Early Eyedrop Refills in the United States.

Q2 Medicine Ophthalmology. Glaucoma Pub Date : 2024-11-12 DOI:10.1016/j.ogla.2024.11.003
Nicole N Chamberlain, J Kevin McKinney, Lydia Yang, Wisam Najdawi, Patrick B Barlow, Andrew E Pouw
{"title":"Analysis of Legal Verbiage in State Legislation for Insurer Coverage of Early Eyedrop Refills in the United States.","authors":"Nicole N Chamberlain, J Kevin McKinney, Lydia Yang, Wisam Najdawi, Patrick B Barlow, Andrew E Pouw","doi":"10.1016/j.ogla.2024.11.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>State laws on early eyedrop refills, implemented to help patients obtain their medications when they run out early, have many inconsistencies possibly impacting their efficacy and functionality. This study sought to examine different state laws and elucidate unique features and commonalities that may influence their effectiveness.</p><p><strong>Design: </strong>A review of all state legislation to date regarding early eyedrop refills was performed.</p><p><strong>Participants: </strong>All 50 states were included, with an in-depth review of the 33 states that had early eyedrop refill legislation.</p><p><strong>Methods: </strong>The law database Nexis Uni (formerly LexisNexis) and each state's individual law code site were used to identify relevant laws (or proposed legislation) using keywords such as \"eyedrop,\" \"eye,\" \"refill,\" and \"early.\" Political data based on the year these laws were passed were obtained from the National Governor's Association and National Conference of State Legislatures. These data were aggregated and analyzed using descriptive statistics.</p><p><strong>Main outcome measures: </strong>State law wording was analyzed for percentage of dosage period passed, days passed, and other requirements.</p><p><strong>Results: </strong>Of the 33 states with early eyedrop refill laws, 14 were only days based, 8 were only percentage based, 4 had both, 4 had neither percentage nor days criteria, and 3 had neither but cited Centers for Medicare and Medicaid Services guidelines. These laws were passed between 2009 and 2023, with a notable increase from 2014 to 2018, rising from 10 to 29 states. Regionally, the Northeast had the highest adoption rate (88%), followed by the West (77%), the South (56%), and the Midwest (50%). Political climates varied: 14 states had Republican control, 2 had Democratic control, and 17 had mixed party control. Of the 17 states without an early eyedrop refill law 4 attempted passage but were not put into law for various reasons with the other 13 not appearing to have had any attempts at law passage.</p><p><strong>Conclusions: </strong>State laws providing coverage for early eyedrop refills vary in terms of verbiage and requirements necessary to obtain a covered early eyedrop refill. Region, political climate, and year appear to play minor roles in early eyedrop refill verbiage and passage.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":56368,"journal":{"name":"Ophthalmology. Glaucoma","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ogla.2024.11.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: State laws on early eyedrop refills, implemented to help patients obtain their medications when they run out early, have many inconsistencies possibly impacting their efficacy and functionality. This study sought to examine different state laws and elucidate unique features and commonalities that may influence their effectiveness.

Design: A review of all state legislation to date regarding early eyedrop refills was performed.

Participants: All 50 states were included, with an in-depth review of the 33 states that had early eyedrop refill legislation.

Methods: The law database Nexis Uni (formerly LexisNexis) and each state's individual law code site were used to identify relevant laws (or proposed legislation) using keywords such as "eyedrop," "eye," "refill," and "early." Political data based on the year these laws were passed were obtained from the National Governor's Association and National Conference of State Legislatures. These data were aggregated and analyzed using descriptive statistics.

Main outcome measures: State law wording was analyzed for percentage of dosage period passed, days passed, and other requirements.

Results: Of the 33 states with early eyedrop refill laws, 14 were only days based, 8 were only percentage based, 4 had both, 4 had neither percentage nor days criteria, and 3 had neither but cited Centers for Medicare and Medicaid Services guidelines. These laws were passed between 2009 and 2023, with a notable increase from 2014 to 2018, rising from 10 to 29 states. Regionally, the Northeast had the highest adoption rate (88%), followed by the West (77%), the South (56%), and the Midwest (50%). Political climates varied: 14 states had Republican control, 2 had Democratic control, and 17 had mixed party control. Of the 17 states without an early eyedrop refill law 4 attempted passage but were not put into law for various reasons with the other 13 not appearing to have had any attempts at law passage.

Conclusions: State laws providing coverage for early eyedrop refills vary in terms of verbiage and requirements necessary to obtain a covered early eyedrop refill. Region, political climate, and year appear to play minor roles in early eyedrop refill verbiage and passage.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分析美国各州立法中有关保险公司承保早期眼药水补给的法律条文。
目的:为帮助患者在药物提前用完时获得药物而实施的关于眼药水提前补充的州法律存在许多不一致之处,可能会影响其有效性和功能性。本研究试图考察不同州的法律,并阐明可能影响其有效性的独特之处和共性:设计:对迄今为止各州有关提前补充眼药水的立法进行了审查:所有 50 个州都包括在内,并对 33 个州的早期眼药水补充立法进行了深入审查:方法:利用法律数据库 Nexis Uni(前身为 LexisNexis)和各州的法律代码网站,使用 "眼药水"、"眼睛"、"笔芯 "和 "早期 "等关键词来识别相关法律(或立法提案)。从全国州长协会和全国州立法会议获得了基于这些法律通过年份的政治数据。对这些数据进行了汇总,并使用描述性统计进行了分析:对各州法律的措辞进行了分析,包括通过的剂量期百分比、通过的天数以及其他要求:在 33 个制定了提前重新配制眼药水法律的州中,14 个州仅以天数为标准,8 个州仅以百分比为标准,4 个州两者兼有,4 个州既无百分比标准也无天数标准,3 个州既无百分比标准也无天数标准,但引用了 CMS 指南。这些法律是在 2009-2023 年间通过的,2014-2018 年间显著增加,从 10 个州增加到 29 个州。从地区来看,东北部采用率最高(88%),其次是西部(77%)、南部(56%)和中西部(50%)。政治气候各不相同:14 个州由共和党控制,2 个州由民主党控制,17 个州由混合党派控制。在 17 个没有制定早期补充眼药水法律的州中,有 4 个州曾试图通过该法律,但由于种种原因未能付诸实施,另外 13 个州似乎没有试图通过该法律:结论:提供早期眼药水补充服务的州法律在措辞和获得早期眼药水补充服务所需的要求方面各不相同。地区、政治气候和年份似乎对早期眼药水补充的措辞和通过起着次要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ophthalmology. Glaucoma
Ophthalmology. Glaucoma Medicine-Medicine (all)
CiteScore
4.20
自引率
0.00%
发文量
140
期刊最新文献
Influence of Social Determinants of Health on Presentation and Outcomes of Primary Congenital Glaucoma. Cost-Effectiveness Analysis of Hydrus Microstent for patients with mild to moderate Primary Open-Angle Glaucoma in Canada. Minimally Invasive Glaucoma Surgery and the Distal Aqueous Outflow System: The Final Frontier? Patient Challenges with Glaucoma Eye Drops: A Need to Identify Nonadherence and Facilitate Appropriate Support and Disease Management. Lost in the Angle: The Mystery of the Missing XEN.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1